evaluated the relationship between the percentage of CD3+CD56+ subset in CIK cells and survival of treated metastatic CRC patients and showed that no significant differences were observed in the OS and progression-free survival (PFS) in higher ratios of CD3+CD56+ subset in the first cycle. Here, NCAM1 is linked to colorectal carcinoma.